

Francois Gueyffier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7143453/publications.pdf>

Version: 2024-02-01

105
papers

7,099
citations

126907

33
h-index

56724

83
g-index

119
all docs

119
docs citations

119
times ranked

9174
citing authors

#	ARTICLE	IF	CITATIONS
1	How do they add up? The interaction between the placebo and treatment effect: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3638-3656.	2.4	9
2	Comparison of crossover and parallelâ€”group designs for the identification of a binary predictive biomarker of the treatment effect. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 59-64.	2.5	2
3	Individual participant data metaâ€”analysis to examine interactions between treatment effect and participantâ€”level covariates: Statistical recommendations for conduct and planning. <i>Statistics in Medicine</i> , 2020, 39, 2115-2137.	1.6	90
4	GLUcose COntrol Safety & Efficacy in type 2 Diabetes, a systematic review and NETwork meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0217701.	2.5	14
5	Investigation of oneâ€”stage metaâ€”analysis methods for joint longitudinal and timeâ€”toâ€”event data through simulation and real data application. <i>Statistics in Medicine</i> , 2019, 38, 247-268.	1.6	5
6	Combined effect of renal function and serum potassium level in sudden cardiac death in aging hypertensive subjects. <i>Hypertension Research</i> , 2018, 41, 469-474.	2.7	7
7	Investigation of 2â€”stage metaâ€”analysis methods for joint longitudinal and timeâ€”toâ€”event data through simulation and real data application. <i>Statistics in Medicine</i> , 2018, 37, 1227-1244.	1.6	4
8	Type 2 diabetes. <i>Lancet, The</i> , 2018, 391, 1261.	13.7	7
9	Effectiveness of drug interventions to prevent sudden cardiac death in patients with heart failure and reduced ejection fraction: an overview of systematic reviews. <i>BMJ Open</i> , 2018, 8, e021108.	1.9	32
10	How to measure the net benefit of treatment?. <i>Therapie</i> , 2017, 72, 51-61.	1.0	3
11	Protocol of GLUcose COntrol Safety and Efficacy in type 2 Diabetes, a NETwork metaâ€”analysis: <scp>GLUCOSE DINET</scp> protocolâ€”Rational and design. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 258-264.	1.9	4
12	Pharmacotherapy for hypertension in adults aged 18 to 59 years. <i>The Cochrane Library</i> , 2017, 2017, CD008276.	2.8	32
13	A sudden death risk score specifically for hypertension. <i>Journal of Hypertension</i> , 2017, 35, 2178-2184.	0.5	5
14	Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials. <i>Diabetes and Metabolism</i> , 2017, 43, 48-58.	2.9	83
15	No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials. <i>PLoS ONE</i> , 2017, 12, e0171168.	2.5	30
16	Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals. <i>The Cochrane Library</i> , 2016, 2016, CD011745.	2.8	15
17	Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials. <i>BMC Endocrine Disorders</i> , 2016, 16, 39.	2.2	41
18	Metformin as firstline treatment for type 2 diabetes: are we sure?. <i>BMJ, The</i> , 2016, 352, h6748.	6.0	26

#	ARTICLE	IF	CITATIONS
19	Translational Research: Precision Medicine, Personalized Medicine, Targeted Therapies: Marketing or Science?. <i>Therapie</i> , 2015, 70, 11-19.	1.0	9
20	High Risk versus Proportional Benefit: Modelling Equitable Strategies in Cardiovascular Prevention. <i>PLoS ONE</i> , 2015, 10, e0140793.	2.5	3
21	Is legacy a myth or a reality? We should know, and we do not. <i>Journal of Hypertension</i> , 2015, 33, 2207-2209.	0.5	1
22	Comparative transcriptomic analysis between an artificially induced SIRS in healthy individuals and spontaneous sepsis. <i>Comptes Rendus - Biologies</i> , 2015, 338, 635-642.	0.2	1
23	Uptake of systematic reviews and meta-analyses based on individual participant data in clinical practice guidelines: descriptive study. <i>BMJ, The</i> , 2015, 350, h1088-h1088.	6.0	51
24	Different treatment benefits were estimated by clinical trials performed in adults compared with those performed in children. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 1221-1231.	5.0	14
25	Pharmacotherapy for mild hypertension. <i>The Cochrane Library</i> , 2014, 2014, CD006742.	2.8	129
26	Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. <i>European Journal of Heart Failure</i> , 2014, 16, 76-85.	7.1	70
27	Impact of the reduction of calcineurin inhibitors on renal function in heart transplant patients: a systematic review and meta-analysis. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 24-32.	2.4	16
28	The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 142.	2.7	43
29	Improving risk prediction performance for a better guidelines application. <i>Journal of Hypertension</i> , 2014, 32, 1192-1193.	0.5	0
30	Cardiovascular Events and Bleeding Risk Associated With Intravitreal Antivasular Endothelial Growth Factor Monoclonal Antibodies. <i>JAMA Ophthalmology</i> , 2014, 132, 1317.	2.5	108
31	Comparison of an effect-model-law-based method versus traditional clinical practice guidelines for optimal treatment decision-making: application to statin treatment in the French population. <i>Journal of the Royal Society Interface</i> , 2014, 11, 20140867.	3.4	6
32	Meta-analysis of a continuous outcome combining individual patient data and aggregate data: a method based on simulated individual patient data. <i>Research Synthesis Methods</i> , 2014, 5, 322-351.	8.7	4
33	Revising the ECRIN standard requirements for information technology and data management in clinical trials. <i>Trials</i> , 2013, 14, 97.	1.6	9
34	Impaired baroreflex sensitivity and the risks of new-onset ambulatory hypertension, in an elderly population-based study. <i>International Journal of Cardiology</i> , 2013, 168, 4010-4014.	1.7	27
35	Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 52.	1.7	106
36	Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure. <i>Clinical Pharmacokinetics</i> , 2013, 52, 199-209.	3.5	31

#	ARTICLE	IF	CITATIONS
37	Impact of Genetic Polymorphism on Drug-Drug Interactions Mediated by Cytochromes: A General Approach. <i>AAPS Journal</i> , 2013, 15, 1242-1252.	4.4	42
38	Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. <i>BMC Medical Research Methodology</i> , 2013, 13, 107.	3.1	10
39	Is there excess mortality in women screened with mammography: a meta-analysis of non-breast cancer mortality. <i>Trials</i> , 2013, 14, 368.	1.6	3
40	Physicians' Knowledge and Practice of Lung Cancer Screening: A Cross-Sectional Survey Comparing General Practitioners, Thoracic Oncologists, and Pulmonologists in France. <i>Clinical Lung Cancer</i> , 2013, 14, 574-580.	2.6	16
41	Expected impact of a public health intervention in the presence of synergistic risk factors. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 445-452.	5.0	0
42	Meta-analysis of randomised trials with a continuous outcome according to baseline imbalance and availability of individual participant data. <i>Statistics in Medicine</i> , 2013, 32, 2747-2766.	1.6	83
43	Pharmacoepidemiology Studies: what Levels of Evidence and how can They be Reached?. <i>Therapie</i> , 2013, 68, 247-252.	1.0	5
44	Clinically Relevant Efficacy of Insulin Therapy in Patients with Type 2 Diabetes. <i>Therapie</i> , 2013, 68, 415-417.	1.0	4
45	Information et participation active des patients À l'aide d'une brochure interactive lors de la prescription d'antihypertenseurs en soins primaires. <i>Sante Publique</i> , 2013, Vol. 25, 193-201.	0.1	3
46	Anti-Trypanosoma cruzi Cross-Reactive Antibodies Detected at High Rate in Non-Exposed Individuals Living in Non-Endemic Regions: Seroprevalence and Association to Other Viral Serologies. <i>PLoS ONE</i> , 2013, 8, e74493.	2.5	9
47	Virtual Patients and Sensitivity Analysis of the Guyton Model of Blood Pressure Regulation: Towards Individualized Models of Whole-Body Physiology. <i>PLoS Computational Biology</i> , 2012, 8, e1002571.	3.2	23
48	Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials. <i>PLoS Medicine</i> , 2012, 9, e1001204.	8.4	217
49	The IDEAL Study : Towards Personalized Drug Treatment of Hypertension. <i>Therapie</i> , 2012, 67, 195-204.	1.0	3
50	Contribution of Modeling Approaches and Virtual Populations in Transposing the Results of Clinical Trials into Real Life and in Enlightening Public Health Decisions. <i>Therapie</i> , 2012, 67, 367-374.	1.0	7
51	Farnesoid X Receptor Targeting for Hepatitis C: Study Protocol for a Proof-of-concept Trial. <i>Therapie</i> , 2012, 67, 423-427.	1.0	3
52	Modeling the impact of cardiovascular prevention strategies. <i>Journal of Hypertension</i> , 2012, 30, 51-52.	0.5	0
53	Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial. <i>Trials</i> , 2012, 13, 231.	1.6	6
54	Oseltamivir+zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. <i>Antiviral Research</i> , 2012, 96, 130-137.	4.1	35

#	ARTICLE	IF	CITATIONS
55	Individual patient data meta-analysis of survival data using Poisson regression models. BMC Medical Research Methodology, 2012, 12, 34.	3.1	66
56	Pharmacotherapy for mild hypertension. Sao Paulo Medical Journal, 2012, 130, 417-418.	0.9	8
57	Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2011, 343, d4169-d4169.	2.3	631
58	Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Critical Care, 2011, 15, R99.	5.8	263
59	The Global Risk Approach Should Be Better Applied in French Hypertensive Patients: A Comparison between Simulation and Observation Studies. PLoS ONE, 2011, 6, e17508.	2.5	20
60	Blood pressure lowering in the oldest old: a step toward abandoning arbitrary blood pressure targets. Journal of Hypertension, 2011, 29, 171-173.	0.5	0
61	How to Improve the Clinical Development Paradigm and its Division into Phases I, II and III. Therapie, 2011, 66, 331-334.	1.0	5
62	<sc>l</sc>â€œasparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005â€œ1 randomized trial. British Journal of Haematology, 2011, 153, 58-65.	2.5	118
63	Standard requirements for GCP-compliant data management in multinational clinical trials. Trials, 2011, 12, 85.	1.6	61
64	Towards personalized medicine: exploring the consequences of the effect model-based approach. Personalized Medicine, 2011, 8, 581-586.	1.5	15
65	Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. Journal of Hypertension, 2010, 28, 1366-1372.	0.5	160
66	Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres. Trials, 2010, 11, 79.	1.6	45
67	Prevention of dementia by antihypertensive drugs: how AT1-receptor-blockers and dihydropyridines better prevent dementia in hypertensive patients than thiazides and ACE-inhibitors. Expert Review of Neurotherapeutics, 2009, 9, 1413-1431.	2.8	120
68	Cognitive Therapy versus Rogerian Supportive Therapy in Borderline Personality Disorder. Psychotherapy and Psychosomatics, 2009, 78, 307-316.	8.8	82
69	SCORE should be preferred to Framingham to predict cardiovascular death in French population. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 609-615.	2.8	17
70	Metaâ€œanalysis of continuous outcomes combining individual patient data and aggregate data. Statistics in Medicine, 2008, 27, 1870-1893.	1.6	222
71	Severe myoclonic epilepsy in infancy: A systematic review and a metaâ€œanalysis of individual patient data. Epilepsia, 2008, 49, 343-348.	5.1	119
72	New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear. Journal of Clinical Epidemiology, 2008, 61, 301-307.	5.0	22

#	ARTICLE	IF	CITATIONS
73	How to Improve Clinical Research Performances in France?. Therapie, 2008, 63, 297-300.	1.0	2
74	Do We Need to Assess the Effect of Treatment Withdrawal?. Stroke, 2007, 38, 2629-2630.	2.0	2
75	Does a change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke?. Journal of Hypertension, 2007, 25, 1543-1553.	0.5	35
76	The JIKEI trial. Lancet, The, 2007, 370, 1825-1826.	13.7	4
77	Estimation of attributable burden of disease: authors'™ reply. Journal of Hypertension, 2006, 24, 981-982.	0.5	0
78	Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Medicine, 2006, 32, 1175-1183.	8.2	442
79	The lower the better: Does simplicity lead to absurdity?. Journal of Hypertension, 2006, 24, 431-433.	0.5	5
80	ModÃ©lisation et essais cliniques en pÃ©diatrie. Therapie, 2005, 60, 379-384.	1.0	1
81	Modelling and Clinical Trials in Paediatrics. Therapie, 2005, 60, 385-390.	1.0	0
82	Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments. Fundamental and Clinical Pharmacology, 2005, 19, 579-584.	1.9	23
83	Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome. Hypertension, 2005, 45, 907-913.	2.7	253
84	The true treatment benefit is unpredictable in clinical trials using surrogate outcome measured with diagnostic tests. Journal of Clinical Epidemiology, 2005, 58, 1042-1051.	5.0	25
85	Treatment of high blood pressure and gain in event-free life expectancy. Vascular Health and Risk Management, 2005, 1, 163-169.	2.3	25
86	Are guidelines right to promote lifestyle interventions against hypertension?. Journal of Hypertension, 2004, 22, 2055-2056.	0.5	1
87	Another benefit from salt intake reduction?. Journal of Hypertension, 2004, 22, 1459-1460.	0.5	1
88	Sub-group analyses. Journal of Hypertension, 2004, 22, 467-469.	0.5	1
89	How should therapeutic information be transferred to users?. Fundamental and Clinical Pharmacology, 2003, 17, 495-503.	1.9	5
90	Absolute benefit, number needed to treat and gain in life expectancy: which efficacy indices for measuring the treatment benefit?. Journal of Clinical Epidemiology, 2003, 56, 977-982.	5.0	19

#	ARTICLE	IF	CITATIONS
91	Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 564-72.	2.3	6
92	Editorial Commentâ€”Secondary Prevention of Stroke: Beyond Meta-Analyses. <i>Stroke</i> , 2003, 34, 2748-2749.	2.0	4
93	Pulsatile blood pressure component as predictor of mortality in hypertension: a meta-analysis of clinical trial control groups. <i>Journal of Hypertension</i> , 2002, 20, 145-151.	0.5	136
94	J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data. <i>Annals of Internal Medicine</i> , 2002, 136, 438.	3.9	253
95	Risk reduction for stroke and coronary events. <i>Lancet, The</i> , 2002, 359, 1249.	13.7	2
96	A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2001, 323, 75-81.	2.3	216
97	Pharmacotherapy for hypertension in women of different races. <i>The Cochrane Library</i> , 2000, , CD002146.	2.8	10
98	Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. <i>Lancet, The</i> , 2000, 355, 865-872.	13.7	1,136
99	Efficacy of treating hypertension in women. <i>Journal of General Internal Medicine</i> , 1999, 14, 718-729.	2.6	30
100	Identification of responders to a therapy: an example of validation of a predictive model. <i>European Journal of Epidemiology</i> , 1999, 15, 559-567.	5.7	3
101	Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 1999, 353, 793-796.	13.7	593
102	Antihypertensive treatment. <i>Lancet, The</i> , 1999, 354, 1028.	13.7	3
103	The Calculation of a Confidence Interval on the Absolute Estimated Benefit for an Individual Patient. <i>Journal of Biomedical Informatics</i> , 1998, 31, 244-256.	0.7	5
104	Effect of Antihypertensive Drug Treatment on Cardiovascular Outcomes in Women and Men. <i>Annals of Internal Medicine</i> , 1997, 126, 761.	3.9	307
105	Response to â€œinclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993 â€” The perspective of NIH clinical trialistsâ€” <i>Contemporary Clinical Trials</i> , 1995, 16, 286-288.	1.9	13